Rani Therapeutics Holdings (RANI) Enterprise Value (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Enterprise Value of -$2.5 million for Q1 2026, up 79.8% year-over-year from -$1.4 million in Q1 2025, and up 75.23% quarter-over-quarter from -$10.1 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Enterprise Value (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Enterprise Value history runs 7 years deep, the most recent figure standing at -$2.5 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 79.8% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$2.5 million (up 79.8% YoY), while the FY2025 annual figure was -$10.1 million, down 347.41% from the prior year.
- Enterprise Value for Q1 2026 stood at -$2.5 million, up from -$10.1 million in the prior quarter.
- The five-year high for Enterprise Value was $57.3 million in Q1 2022, with the low at -$88.4 million in Q4 2022.
- The 5-year median for Enterprise Value is -$1.6 million (2024), against an average of $1.9 million.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value soared 173.35% in 2022, then slumped 4870.77% in 2025.
- Rani Therapeutics Holdings' Enterprise Value stood at -$88.4 million in 2022, then jumped by 107.6% to $6.7 million in 2023, then tumbled by 133.68% to -$2.3 million in 2024, then tumbled by 347.41% to -$10.1 million in 2025, then surged by 75.23% to -$2.5 million in 2026.
- Business Quant data shows RANI's Enterprise Value at -$2.5 million in Q1 2026, -$10.1 million in Q4 2025, and -$8.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - | -44.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.65 Mn |
| Mar 31, 2026 | -2.51 Mn |
| Dec 31, 2025 | -10.12 Mn |
| Sep 30, 2025 | -8.26 Mn |
| Jun 30, 2025 | -13.79 Mn |
| Mar 31, 2025 | -12.40 Mn |
| Dec 31, 2024 | -2.26 Mn |
| Sep 30, 2024 | -1.62 Mn |
| Jun 30, 2024 | -1.80 Mn |
| Mar 31, 2024 | 260,000.00 |
| Dec 31, 2023 | 6.71 Mn |
| Sep 30, 2023 | 12.29 Mn |
| Jun 30, 2023 | 16.52 Mn |
| Mar 31, 2023 | 11.88 Mn |
| Dec 31, 2022 | -88.36 Mn |
| Sep 30, 2022 | 17.19 Mn |
| Jun 30, 2022 | 50.84 Mn |
| Mar 31, 2022 | 57.26 Mn |
| Dec 31, 2021 | -43.30 Mn |
| Sep 30, 2021 | -49.40 Mn |